This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ciampelli, M. Articles by Lanzone, A. Search for Related Content PubMed PubMed Citation Articles by Ciampelli, M. Articles by Lanzone, A.

Metabolic and Endocrine Consequences of Acute Suppression of FFAs by Acipimox in Polycystic Ovary Syndrome

Department of Obstetrics and Gynecology (M.C., G.M., F.L., D.R., C.B.), Università Cattolica del Sacro Cuore, 00168 Roma; and OASI Institute For Research (R.M.C., A.L.), Troina 94018 (Enna), Italy

Address all correspondence and requests for reprints to: Antonio Lanzone, M.D., Department of Obstetrics and Gynecology, Università Cattolica del Sacro Cuore, L.go A. Gemelli 8, 00168 Roma, Italy. E-mail: alanzone{at}rm.unicatt.it

Abstract

To evaluate the effects of acute lowering of FFAs on glucose-induced insulin secretion and GH response to GHRH in polycystic ovary syndrome (PCOS), 27 PCOS subjects (11 lean and 16 obese) and 17 body mass index-matched controls (8 lean and 9 obese) were investigated.

Patients underwent an oral glucose tolerance test and a GHRH test before and after administration of the antilipolytic drug acipimox (250 mg orally 3 h and 1 h before the starting of the tests).

Blood samples were collected for 2 h after GHRH bolus and for 4 h after the oral glucose tolerance test. Serum concentrations of GH, insulin, glucose, and c-peptide were assayed in each sample, and the results were expressed as area under the curve (AUC).

No significant differences were found as to glucose, insulin, and c-peptide AUC before and after acute FFA plasma reduction in any of the investigated groups. Basally, lower GH-AUC was found in lean PCOS compared with body mass index-matched controls and in obese vs. lean controls; no significant differences were found as to the same variable between the two obese groups. The acipimox induced FFA suppression elicited in the four groups a sustained increase in the GH response to its trophic hormone; indeed, the GH-AUC nearly doubled with respect to basal evaluation in all the studied groups. However, the antilipolytic drug was not able to abolish the differences found between lean groups in basal conditions.

In conclusion, the presented data confirm that FFAs have a main role in regulating GH secretion at the pituitary level; however, it does not seem that they could explain the GH as well as insulin dysfunction of PCOS.

This article has been cited by other articles:

				D. Glintborg, R. K. Stoving, C. Hagen, A. P. Hermann, J. Frystyk, J. D. Veldhuis, A. Flyvbjerg, and M. Andersen Pioglitazone Treatment Increases Spontaneous Growth Hormone (GH) Secretion and Stimulated GH Levels in Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., October 1, 2005; 90(10): 5605 - 5612. [Abstract] [Full Text] [PDF]

				L. De Marinis, A. Bianchi, A. Mancini, R. Gentilella, M. Perrelli, A. Giampietro, T. Porcelli, L. Tilaro, A. Fusco, D. Valle, et al. Growth Hormone Secretion and Leptin in Morbid Obesity before and after Biliopancreatic Diversion: Relationships with Insulin and Body Composition J. Clin. Endocrinol. Metab., January 1, 2004; 89(1): 174 - 180. [Abstract] [Full Text] [PDF]